# A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

> **NCT05443724** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 700 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CVL-231 30 mg

## Key facts

- **NCT ID:** NCT05443724
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-02
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443724, "A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05443724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*